Core Viewpoint - Novavax has raised its annual revenue forecast for the third time this year, driven by milestone payments from vaccine supply and licensing agreements, particularly with Takeda Pharmaceuticals in Japan [1] Group 1 - The company has increased its revenue outlook, indicating strong performance and confidence in its vaccine-related business [1] - The adjustments in revenue forecast are attributed to successful partnerships and agreements in the vaccine sector [1]

Core Viewpoint - Moderna has reduced the upper limit of its 2025 revenue forecast by $200 million due to lower-than-expected sales of its COVID-19 vaccine in the U.S. market, as access to the vaccine has been a challenge for Americans [1] Company Summary - Moderna's adjustment in revenue forecast reflects a significant impact from the sales performance of its COVID-19 vaccine [1] - The company is facing challenges related to vaccine accessibility, which has contributed to the weaker sales figures [1]

Core Insights - Palantir Technologies Inc. raised its annual revenue forecast following a stronger-than-expected third quarter performance [1] - The company's revenue increased by 63% year-over-year, reaching $1 billion [1] - Despite the positive earnings report, shares of Palantir fell in extended trading as investors expressed concerns over the company's high valuation [1]